Skip to main content
Equibles

Dale Sander

CFO

Humacyte, Inc. (HUMA)

Equibles does not estimate personal net worth.

Get an email with a short summary when Humacyte, Inc. publishes a filing, an earnings call transcript or a press release.

Get HUMA alerts

About Dale Sander

Dale Sander is recorded as CFO at Humacyte, Inc. (HUMA). The proxy statement of Humacyte, Inc. reports total compensation of $2,131,658 for Dale Sander in fiscal 2025, including a base salary of $545,968. Disclosed compensation is on record for 5 fiscal years. Dale Sander has spoken on 20 earnings calls across 1 company, most recently for Humacyte, Inc. on November 10, 2026. Humacyte, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Humacyte, Inc. includes Laura E. Niklason (CEO and Board Member), Laura Niklason (CEO and Board Member), Dale A. Sander (CFO) and 7 others.

Dale Sander on recent calls

“Commercial sales of SimVest increased to $1 million for the third quarter of 2026 compared to $0.4 million in the second quarter of 2026 and $0.7 million in the third quarter of 2025.”
CFO, Humacyte Third Quarter 2026 Financial Results and Corporate Update ·
“Commercial sales were $0.4 million in the second quarter of 2026, which is really a rebuilding quarter, compared to $0.1 million for the second quarter of 2025.”
CFO, Humacyte, Inc. Q2 FY2026 Earnings Call ·
“Commercial sales with Symbest were 0.5 million, or 29 units, in the first quarter of 2026, compared to 0.1 million, or 5 units, in the first quarter of 2025.”
CFO, Humacyte, Inc. Q1 FY2026 Earnings Call ·
“There was $0.5 million in revenue for the three-month ended December 31, 2025, of which $0.4 million related to U.S. sales of 25 CIMBES units.”
CFO, Humacyte, Inc. Q4 FY2025 Earnings Call ·
“Revenue for the three months ended September 30, 2025, was $0.8 million, of which $0.7 million related to U.S. sales of Symvess. The remaining $0.1 million resulted from a research collaboration with a large medical technology company.”
CFO, Humacyte, Inc. Q3 FY2025 Earnings Call ·

Affiliation history

Company network

Leadership on record at Humacyte, Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 Humacyte, Inc. (HUMA) $545,968 $2,131,658
2024 Humacyte, Inc. (HUMA) $505,750 $704,189
2023 Humacyte, Inc. (HUMA) $504,471 $1,351,483
2022 Humacyte, Inc. (HUMA) $488,419 $982,969
2021 Humacyte, Inc. (HUMA) — —

Recent activity

Show 8 earlier activities